Veli Kairisto
Publications
- Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group (2022)
- European Journal of Haematology
(A1 Refereed original research article in a scientific journal) - Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers (2022)
- Virchows Archiv
(A1 Refereed original research article in a scientific journal) - Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study (2022)
- Leukemia
(A1 Refereed original research article in a scientific journal) - Tool evaluation for the detection of variably sized indels from next generation whole genome and targeted sequencing data (2022)
- PLoS Computational Biology
(A1 Refereed original research article in a scientific journal) - Geeniohjatun syövän hoidon työryhmä hoitopäätösten apuna : Läntisen syöpäkeskuksen kokemus (2021)
- Duodecim
(D1 Article in a professional journal) - Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia (2020)
- British Journal of Haematology
(A1 Refereed original research article in a scientific journal) - Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia (2019)
- Cancers
(A1 Refereed original research article in a scientific journal) - Hematologisen syöpäpotilaan diagnostinen polku (2019)
- Duodecim
(D1 Article in a professional journal) - Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (2019)
- Leukemia
(A1 Refereed original research article in a scientific journal) - Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial (2018)
- Lancet Oncology
(A1 Refereed original research article in a scientific journal)



